These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22261540)

  • 1. Anemia in the nursing homes: a complex issue.
    Morley JE
    J Am Med Dir Assoc; 2012 Mar; 13(3):191-4. PubMed ID: 22261540
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 4. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized doses of epoetin alfa for hemodialysis patients.
    Nguyen TV; Iacovino LA
    Am J Health Syst Pharm; 2005 Sep; 62(18):1867. PubMed ID: 16141103
    [No Abstract]   [Full Text] [Related]  

  • 7. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 8. Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
    Gabrilove JL; Sarokhan B; Cremieux P
    J Clin Oncol; 2002 Jun; 20(11):2757-8. PubMed ID: 12039942
    [No Abstract]   [Full Text] [Related]  

  • 9. Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment.
    Henry DH
    Blood; 2003 Oct; 102(7):2697-8. PubMed ID: 14504070
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation.
    Nguyen TV; Trinh GN
    J Clin Oncol; 2002 Feb; 20(3):878. PubMed ID: 11821478
    [No Abstract]   [Full Text] [Related]  

  • 11. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
    Lynch DM; Slaven T
    Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of epoetin dose on hematocrit.
    Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
    Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 19. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?
    Bottomley A; Thomas R; van Steen K; Flechtner H; Djulbegovic B
    Lancet Oncol; 2002 Mar; 3(3):145-53. PubMed ID: 11902500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.